Home » Stocks » BioCardia

BioCardia, Inc. (BCDA)

Stock Price: $2.74 USD 0.17 (6.61%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed
After-hours: $2.72 -0.02 (-0.73%) Aug 5, 5:10 PM

Stock Price Chart

Key Info

Market Cap 33.85M
Revenue (ttm) 532,000
Net Income (ttm) -15.64M
Shares Out 12.32M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $2.74
Previous Close $2.57
Change ($) 0.17
Change (%) 6.61%
Day's Open 2.55
Day's Range 2.52 - 2.79
Day's Volume 307,933
52-Week Range 2.01 - 7.25

More Stats

Market Cap 33.85M
Enterprise Value 32.28M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.32M
Float 4.03M
EPS (basic) -2.55
EPS (diluted) -2.49
FCF / Share -1.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 58,689
Short Ratio 0.11
Short % of Float 0.57%
Beta 2.27
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 63.63
PB Ratio 3.93
Revenue 532,000
Operating Income -15.13M
Net Income -15.64M
Free Cash Flow -10.07M
Net Cash 1.57M
Net Cash / Share 0.13
Gross Margin -1,543.23%
Operating Margin -2,844.55%
Profit Margin -2,933.80%
FCF Margin -1,892.67%
ROA -198.29%
ROE -364.95%
ROIC 1,563.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$16.50*
(502.19% upside)
Low
9.00
Current: $2.74
High
24.00
Target: 16.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.710.630.480.580.900.430.270.060.01-
Revenue Growth13.6%30.48%-16.84%-36.28%111.71%59.33%332.26%416.67%--
Gross Profit0.350.11-0.21-0.17-0.160.430.270.060.01-
Operating Income-14.21-14.10-12.41-7.61-5.410.230.01-0.34-0.62-0.58
Net Income-14.71-13.99-12.31-10.31-6.700.230.020.319.66-11.51
Shares Outstanding5.644.264.240.930.172.132.132.132.132.13
Earnings Per Share-2.61-3.28-2.90-11.07-38.61---4.32-5.40
Operating Cash Flow-9.45-11.07-8.67-5.52-7.020.210.03-0.31-3.09-4.28
Capital Expenditures-0.15-0.07-0.14--0.13----0.14-1.07
Free Cash Flow-9.59-11.14-8.81-5.52-7.150.210.03-0.31-3.22-5.35
Cash & Equivalents5.595.3612.6921.353.5613.5113.3013.2713.580.16
Total Debt1.14---6.72----0.50
Net Cash / Debt4.445.3612.6921.35-3.1613.5113.3013.2713.58-0.34
Assets7.686.4213.5422.084.8613.5513.3313.3013.735.44
Liabilities5.312.632.411.508.30-0.020.010.762.16
Book Value2.373.7911.1320.58-3.4413.5413.3113.2912.983.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioCardia, Inc.
Country United States
Employees 20
CEO Peter Alan Altman

Stock Information

Ticker Symbol BCDA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCDA

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.